{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:57:11Z","timestamp":1792497431125,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40264-020-01026-y","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T10:03:00Z","timestamp":1608112980000},"page":"273-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review"],"prefix":"10.1007","volume":"44","author":[{"given":"Peter","family":"Calverley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4088\/JCP.13m08411","volume":"75","author":"JE Grant","year":"2014","unstructured":"Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LR, Donahue CB, Kim SW. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75:39\u201345.","journal-title":"J Clin Psychiatry"},{"key":"1026_CR2","first-page":"2114","volume":"41","author":"J Kay","year":"2003","unstructured":"Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. N-Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and in intervention: a randomized controlled trial. J Am Med Assoc. 2003;41:2114\u20138.","journal-title":"J Am Med Assoc"},{"key":"1026_CR3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ahj.2004.05.015","volume":"148","author":"SE Miner","year":"2004","unstructured":"Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, et al. N-Acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690\u20135.","journal-title":"Am Heart J"},{"key":"1026_CR4","first-page":"2469486","volume":"2018","author":"SL Ooi","year":"2018","unstructured":"Ooi SL, Green R, Pak SC. N-Acetylcysteine for the treatment of psychiatric disorders: a review of current evidence. Biomed Res Int. 2018;2018:2469486.","journal-title":"Biomed Res Int"},{"key":"1026_CR5","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.3390\/molecules23123305","volume":"23","author":"G Tardiolo","year":"2018","unstructured":"Tardiolo G, Bramanti P, Mazzon E. Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules. 2018;23:3305. https:\/\/doi.org\/10.3390\/molecules23123305.","journal-title":"Molecules"},{"key":"1026_CR6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/0016-5085(95)90758-0","volume":"109","author":"AJ Makin","year":"1995","unstructured":"Makin AJ, Wendon J, William RA. A 7 year experience of severe acetaminophen-induced hepatotoxicity (1987\u20131993). Gastroenterology. 1995;109:1907\u201316.","journal-title":"Gastroenterology"},{"key":"1026_CR7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198812153192401","volume":"319","author":"MJ Smilkstein","year":"1988","unstructured":"Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the National Multicenter Study (1976\u20131985). N Engl J Med. 1988;319:1557\u201362.","journal-title":"N Engl J Med"},{"key":"1026_CR8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/1319-2442.174072","volume":"27","author":"M Habib","year":"2016","unstructured":"Habib M, Hillis A, Hammad A. N-Acetylcysteine and\/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: the NAPCIN trial; a single-center, prospective, randomized trial. Saudi J Kidney Dis Transpl. 2016;27:55\u201361.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"1026_CR9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0735-1097(03)00487-X","volume":"41","author":"CS Baker","year":"2003","unstructured":"Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am CollCardiol. 2003;41:2114\u20138.","journal-title":"J Am CollCardiol"},{"key":"1026_CR10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ehj.2003.11.016","volume":"25","author":"C Briguori","year":"2004","unstructured":"Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206\u201311.","journal-title":"Eur Heart J"},{"key":"1026_CR11","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. https:\/\/goldcopd.org."},{"key":"1026_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jcm7080201","volume":"7","author":"SL Barratt","year":"2018","unstructured":"Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. J Clin Med. 2018;7:201. https:\/\/doi.org\/10.3390\/jcm7080201.","journal-title":"J Clin Med"},{"key":"1026_CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","volume":"16","author":"C Stey","year":"2000","unstructured":"Stey C, Steurer J, Bachmann S, Medici TC, Tram\u00e8r MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. EurRespir J. 2000;16:253\u201362.","journal-title":"EurRespir J"},{"key":"1026_CR14","first-page":"209","volume":"22","author":"EM Grandjean","year":"2000","unstructured":"Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. ClinTher. 2000;22:209\u201321.","journal-title":"ClinTher"},{"key":"1026_CR15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000029447","volume":"66","author":"R Pela","year":"1999","unstructured":"Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-Acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999;66:495\u2013500.","journal-title":"Respiration"},{"key":"1026_CR16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/rmed.2001.1066","volume":"95","author":"M Kasielski","year":"2001","unstructured":"Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001;95:448\u201356.","journal-title":"Respir Med"},{"key":"1026_CR17","first-page":"381","volume":"14","author":"D Nowak","year":"1999","unstructured":"Nowak D, Carati L, Pirozynski M. Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary diseases. Report of the BREATHE study. EurRespir J. 1999;14:381\u20132.","journal-title":"EurRespir J"},{"key":"1026_CR18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","volume":"365","author":"M Decramer","year":"2005","unstructured":"Decramer M, Rutten-van M\u00f6lken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cost-utility study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552\u201360.","journal-title":"Lancet"},{"key":"1026_CR19","first-page":"451","volume":"24","author":"M Cazzola","year":"2015","unstructured":"Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. EurRespir Rev. 2015;24:451\u201361.","journal-title":"EurRespir Rev"},{"key":"1026_CR20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0954-6111(05)80337-3","volume":"88","author":"NC Hansen","year":"1994","unstructured":"Hansen NC, Skriver A, Brorsen-Riis L, Balsl\u00f8v S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88:531\u20135.","journal-title":"Respir Med"},{"key":"1026_CR21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, PANTHEON study group, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomized, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187\u201394.","journal-title":"Lancet Respir Med"},{"key":"1026_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.12-2357","volume":"144","author":"HN Tse","year":"2013","unstructured":"Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144:106\u201318.","journal-title":"Chest"},{"key":"1026_CR23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.13-2784","volume":"146","author":"HN Tse","year":"2014","unstructured":"Tse HN, Raiteri L, Wong KY, Ng LY, Yee KS, Tseng CZ. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. Chest. 2014;146:611\u201323.","journal-title":"Chest"},{"key":"1026_CR24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.09-0421","volume":"136","author":"D Stav","year":"2009","unstructured":"Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009;136:381\u20136.","journal-title":"Chest"},{"key":"1026_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-4-13","volume":"4","author":"PN Black","year":"2004","unstructured":"Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomized, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease ISRCTN21676344. BMC Pulm Med. 2004;4:13.","journal-title":"BMC Pulm Med"},{"key":"1026_CR26","first-page":"6379","volume":"9","author":"JQ Zhang","year":"2015","unstructured":"Zhang JQ, Zhang JQ, Fang LZ, Liu L, Fu WP, Dai LM. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter. Drug Des DevelTher. 2015;9:6379\u201387.","journal-title":"Drug Des DevelTher"},{"key":"1026_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12931-019-1078-y","volume":"20","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20:104.","journal-title":"Respir Res"},{"key":"1026_CR28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-019-1042-x","volume":"20","author":"Q Qi","year":"2019","unstructured":"Qi Q, Ailiyaer Y, Liu R, Zhang Y, Li C, Liu M, et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019;20:73.","journal-title":"Respir Res"},{"issue":"122","key":"1026_CR29","first-page":"1351","volume":"2017","author":"DM Hirai","year":"1985","unstructured":"Hirai DM, Jones JH, Zelt JT, da Silva ML, Bentley RF, Edgett BA, et al. Oral N-acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease. J ApplPhysiol. 1985;2017(122):1351\u201361.","journal-title":"J ApplPhysiol"},{"key":"1026_CR30","first-page":"799","volume":"11","author":"K Johnson","year":"2016","unstructured":"Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J ChronObstrPulm Dis. 2016;11:799\u2013807.","journal-title":"Int J ChronObstrPulm Dis"},{"key":"1026_CR31","first-page":"221ra15","volume":"6","author":"VI Sayin","year":"2014","unstructured":"Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. SciTransl Med. 2014;6:221ra15.","journal-title":"SciTransl Med"},{"key":"1026_CR32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1183\/09031936.00072511","volume":"40","author":"LA De Backer","year":"2012","unstructured":"De Backer LA, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, De Backer W. The acute effect of budesonide\/formoterol in COPD: a multi-slice computed tomography and lung function study. EurRespir J. 2012;40:298\u2013305.","journal-title":"EurRespir J"},{"key":"1026_CR33","first-page":"569","volume":"8","author":"J De Backer","year":"2013","unstructured":"De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel PM, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J ChronObstrPulm Dis. 2013;8:569\u201379.","journal-title":"Int J ChronObstrPulm Dis"},{"key":"1026_CR34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/thx.49.7.670","volume":"49","author":"MM Bridgeman","year":"1994","unstructured":"Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax. 1994;49:670\u20135.","journal-title":"Thorax"},{"key":"1026_CR35","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1164\/ajrccm.156.6.9706065","volume":"156","author":"J Behr","year":"1997","unstructured":"Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosingalveolitis: adjunctive therapy to maintenance immunosuppression. Am J RespirCrit Care Med. 1997;156:1897\u2013901.","journal-title":"Am J RespirCrit Care Med"},{"key":"1026_CR36","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, IFIGENIA Study Group, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229\u201342.","journal-title":"N Engl J Med"},{"key":"1026_CR37","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968\u201377.","journal-title":"N Engl J Med"},{"key":"1026_CR38","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"FJ Martinez","year":"2014","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093\u2013101.","journal-title":"N Engl J Med"},{"key":"1026_CR39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","volume":"192","author":"JM Oldham","year":"2015","unstructured":"Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, IPFnet Investigators, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J RespirCrit Care Med. 2015;192:1475\u201382.","journal-title":"Am J RespirCrit Care Med"},{"key":"1026_CR40","doi-asserted-by":"crossref","first-page":"e1600","DOI":"10.1097\/MD.0000000000001600","volume":"94","author":"H Huang","year":"2015","unstructured":"Huang H, Dai HP, Kang J, Chen BY, Sun TY, Xu ZJ. Double-blind randomized trial of pirfenidone in Chinese idiopathic pulmonary fibrosis patients. Medicine (Baltimore). 2015;94:e1600.","journal-title":"Medicine (Baltimore)"},{"key":"1026_CR41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","volume":"4","author":"J Behr","year":"2016","unstructured":"Behr J, Bendstrup E, Crestani B, G\u00fcnther A, Olschewski H, Sk\u00f6ld CM, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4:445\u201353.","journal-title":"Lancet Respir Med"},{"key":"1026_CR42","first-page":"77","volume-title":"Drugs in bronchial mucology","author":"GP Ventresca","year":"1989","unstructured":"Ventresca GP, Cicchetti V, Ferrari V. Thiols. In: Braga PC, Allegra L, editors. Drugs in bronchial mucology. New York: Raven Press; 1989. p. 77\u2013102."},{"key":"1026_CR43","first-page":"501","volume":"125","author":"KB Adler","year":"1986","unstructured":"Adler KB, Hendley DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol. 1986;125:501\u201314.","journal-title":"Am J Pathol"},{"key":"1026_CR44","first-page":"CD007168","volume":"7","author":"J Tam","year":"2013","unstructured":"Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev. 2013;7:CD007168.","journal-title":"Cochrane Database Syst Rev"},{"key":"1026_CR45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","volume":"14","author":"C Conrad","year":"2015","unstructured":"Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015;14:219\u201327.","journal-title":"J Cyst Fibros"},{"key":"1026_CR46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcf.2014.09.015","volume":"14","author":"M Skov","year":"2015","unstructured":"Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen P\u00d8, Johansen HK, et al. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection: a pilot study. J Cyst Fibros. 2015;14:211\u20138.","journal-title":"J Cyst Fibros"},{"key":"1026_CR47","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","volume":"103","author":"R Tirouvanziam","year":"2006","unstructured":"Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. ProcNatlAcadSci USA. 2006;103:4628\u201333.","journal-title":"ProcNatlAcadSci USA"},{"key":"1026_CR48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/ajrccm.152.3.7663783","volume":"152","author":"A Meyer","year":"1995","unstructured":"Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J RespirCrit Care Med. 1995;152:1055\u201360.","journal-title":"Am J RespirCrit Care Med"},{"key":"1026_CR49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1843.2012.02132.x","volume":"17","author":"S Homma","year":"2012","unstructured":"Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Japan NAC Clinical Study Group, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17:467\u201377.","journal-title":"Respirology"},{"key":"1026_CR50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s40064-015-1455-z","volume":"4","author":"R Okuda","year":"2015","unstructured":"Okuda R, Matsushima H, Aoshiba K, Oba T, Kawabe R, Honda K, et al. Soluble intercellular adhesion molecule-1 for stable and acute phases of idiopathic pulmonary fibrosis. Springerplus. 2015;4:657.","journal-title":"Springerplus"},{"key":"1026_CR51","first-page":"170","volume":"54","author":"Y Muramatsu","year":"2016","unstructured":"Muramatsu Y, Sugino K, Ishida F, Tatebe J, Morita T, Homma S. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. RespirInvestig. 2016;54:170\u20138.","journal-title":"RespirInvestig"},{"key":"1026_CR52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/resp.12477","volume":"20","author":"S Sakamoto","year":"2015","unstructured":"Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology. 2015;20:445\u201352.","journal-title":"Respirology"},{"key":"1026_CR53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0140-6736(91)90350-X","volume":"338","author":"Z Borok","year":"1991","unstructured":"Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet. 1991;338:215\u20136.","journal-title":"Lancet"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-020-01026-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T17:50:55Z","timestamp":1613757055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-020-01026-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-01026-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Peter Calverley has received consulting and personal fees from AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Regeneron Sanofi, Recipharm, Philips Medical and Zambon Company SpA, who sponsored this analysis. Paola Rogliani participated as a lecturer, speaker, and advisor for Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. Her department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici. Alberto Papi reports grants, personal fees, and\/or reimbursement of travel expenses from AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, and Zambon.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the review conception and design, and revised and commented on all versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}